311 related articles for article (PubMed ID: 12437489)
1. Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease?
Doggrell SA
Expert Opin Pharmacother; 2002 Nov; 3(11):1543-56. PubMed ID: 12437489
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II receptor blockers in older patients.
Weber MA
Am J Geriatr Cardiol; 2004; 13(4):197-205; quiz 206-7. PubMed ID: 15269566
[TBL] [Abstract][Full Text] [Related]
4. The future of angiotensin II inhibition in cardiovascular medicine.
Meier P; Maillard M; Burnier M
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Feb; 5(1):15-30. PubMed ID: 15720221
[TBL] [Abstract][Full Text] [Related]
5. Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism.
Brunner-La Rocca HP; Vaddadi G; Esler MD
J Am Coll Cardiol; 1999 Apr; 33(5):1163-73. PubMed ID: 10193712
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin receptor blockers: evidence for preserving target organs.
Carson P; Giles T; Higginbotham M; Hollenberg N; Kannel W; Siragy HM
Clin Cardiol; 2001 Mar; 24(3):183-90. PubMed ID: 11288962
[TBL] [Abstract][Full Text] [Related]
7. ACE inhibitors in heart failure: prospects and limitations.
Pitt B
Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():285-90. PubMed ID: 9211022
[TBL] [Abstract][Full Text] [Related]
8. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases.
Lüscher TF; Wenzel RR; Moreau P; Takase H
Cardiovasc Drugs Ther; 1995 Aug; 9 Suppl 3():509-23. PubMed ID: 8562468
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
Messerli FH; Bangalore S; Bavishi C; Rimoldi SF
J Am Coll Cardiol; 2018 Apr; 71(13):1474-1482. PubMed ID: 29598869
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin receptor antagonists and ACE inhibitors.
Howes LG; Christie N
Aust Fam Physician; 1998 Oct; 27(10):914-7, 919-21. PubMed ID: 9798290
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II-receptor blockers: clinical relevance and therapeutic role.
Rodgers JE; Patterson JH
Am J Health Syst Pharm; 2001 Apr; 58(8):671-83. PubMed ID: 11329759
[TBL] [Abstract][Full Text] [Related]
13. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists.
Campbell DJ
Clin Exp Pharmacol Physiol Suppl; 1996; 3():S125-31. PubMed ID: 8993851
[TBL] [Abstract][Full Text] [Related]
14. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.
Ball SG; White WB
Am J Cardiol; 2003 May; 91(10A):15G-21G. PubMed ID: 12781904
[TBL] [Abstract][Full Text] [Related]
15. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Pfeffer MA
Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
[TBL] [Abstract][Full Text] [Related]
16. Is there a place for combining angiotensin-converting enzyme inhibitors and angiotensin-receptor antagonists in the treatment of hypertension, renal disease or congestive heart failure?
Taylor AA
Curr Opin Nephrol Hypertens; 2001 Sep; 10(5):643-8. PubMed ID: 11496059
[TBL] [Abstract][Full Text] [Related]
17. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Zeller A; Battegay E
Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
[TBL] [Abstract][Full Text] [Related]
18. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers.
Weir MR; Henrich WL
Curr Opin Nephrol Hypertens; 2000 Jul; 9(4):403-11. PubMed ID: 10926177
[TBL] [Abstract][Full Text] [Related]
19. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection.
Parmley WW
Am J Med; 1998 Jul; 105(1A):27S-31S. PubMed ID: 9707265
[TBL] [Abstract][Full Text] [Related]
20. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
Schnack C; Schernthaner G
Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
